Core Viewpoint - Yidu Technology (2158.HK) shares increased by 5.91% to HKD 6.09 following the announcement of a significant project win in clinical research [1] Group 1: Company Developments - Yidu Technology's affiliate, Tianjin Happy Life Technology Co., Ltd., won a bid for the Phase III clinical research project of the human nerve growth factor (SMR001) eye drops from Shandong Yandu Biotechnology Co., Ltd. The total project amount is approximately CNY 55.82 million [1] - The company utilizes its proprietary core algorithm engine, YiduCore, to create a "data-algorithm-scenario" closed-loop system, enabling efficient innovation and low-cost scalable applications of AI technology [1] Group 2: Industry Impact - The implementation of AI technology is driving intelligent decision-making across the entire healthcare ecosystem, which includes medicine, pharmaceuticals, insurance, and patients [1]
港股异动｜医渡科技涨约6% 中标重组人神经生长因子(SMR001)滴眼液III期临床研究项目